MedPath

Effect of Kalonji in Polycystic Ovary

Phase 2
Conditions
Health Condition 1: E282- Polycystic ovarian syndrome
Registration Number
CTRI/2024/07/071331
Lead Sponsor
State TakmeelutTib College and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Married & Unmarried females 18 years and above

Rotterdam criteria (any two out of three)

Clinical or biochemical hyperandrogenism

Evidence of oligo-anovulation

Polycystic appearing-ovarian morphology on Ultrasound

BMI above 25kg per meter square

Exclusion Criteria

Pregnant lactating and menopausal women

Patients with systemic and other endocrinal illness

History of malignancy

Patients with other pelvic pathology

Patients on oral contraceptive pills and IUCDs

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Regulation of menstrual cycle <br/ ><br>Change in polycystic ovarian morphology in USGTimepoint: 90 days
Secondary Outcome Measures
NameTimeMethod
Weight reduction Reduction in BMI <br/ ><br>Decreased Waist to Hip Ratio <br/ ><br>Lipid profile <br/ ><br>Decreases clinical sign of androgen excess Ferriman Gallwey score <br/ ><br>Decrease in Acanthosis nigricans score <br/ ><br>Conception rate in married femalesTimepoint: 90 days
© Copyright 2025. All Rights Reserved by MedPath